Cargando…

Evidence of pioneer factor activity of an oncogenic fusion transcription factor

Recent characterizations of pioneer transcription factors provide insights into their structures and patterns of chromatin recognition associated with their roles in cell fate commitment and transformation. Intersecting with these basic science concepts, identification of pioneer factors (PFs) fused...

Descripción completa

Detalles Bibliográficos
Autores principales: Sunkel, Benjamin D., Wang, Meng, LaHaye, Stephanie, Kelly, Benjamin J., Fitch, James R., Barr, Frederic G., White, Peter, Stanton, Benjamin Z.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346656/
https://www.ncbi.nlm.nih.gov/pubmed/34386729
http://dx.doi.org/10.1016/j.isci.2021.102867
_version_ 1783734923493900288
author Sunkel, Benjamin D.
Wang, Meng
LaHaye, Stephanie
Kelly, Benjamin J.
Fitch, James R.
Barr, Frederic G.
White, Peter
Stanton, Benjamin Z.
author_facet Sunkel, Benjamin D.
Wang, Meng
LaHaye, Stephanie
Kelly, Benjamin J.
Fitch, James R.
Barr, Frederic G.
White, Peter
Stanton, Benjamin Z.
author_sort Sunkel, Benjamin D.
collection PubMed
description Recent characterizations of pioneer transcription factors provide insights into their structures and patterns of chromatin recognition associated with their roles in cell fate commitment and transformation. Intersecting with these basic science concepts, identification of pioneer factors (PFs) fused together as driver translocations in childhood cancers raises questions of whether these fusions retain the fundamental ability to invade repressed chromatin, consistent with their monomeric PF constituents. This study defines the cellular and chromatin localization of PAX3-FOXO1, an oncogenic driver of childhood rhabdomyosarcoma (RMS), derived from a fusion of PFs. To quantitatively define its chromatin-targeting functions and capacity to drive epigenetic reprogramming, we developed a ChIP-seq workflow with per-cell normalization (pc-ChIP-seq). Our quantitative localization studies address structural variation in RMS genomes and reveal insights into inactive chromatin localization of PAX3-FOXO1. Taken together, our studies are consistent with pioneer function for a driver oncoprotein in RMS, with repressed chromatin binding and nucleosome-motif targeting.
format Online
Article
Text
id pubmed-8346656
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83466562021-08-11 Evidence of pioneer factor activity of an oncogenic fusion transcription factor Sunkel, Benjamin D. Wang, Meng LaHaye, Stephanie Kelly, Benjamin J. Fitch, James R. Barr, Frederic G. White, Peter Stanton, Benjamin Z. iScience Article Recent characterizations of pioneer transcription factors provide insights into their structures and patterns of chromatin recognition associated with their roles in cell fate commitment and transformation. Intersecting with these basic science concepts, identification of pioneer factors (PFs) fused together as driver translocations in childhood cancers raises questions of whether these fusions retain the fundamental ability to invade repressed chromatin, consistent with their monomeric PF constituents. This study defines the cellular and chromatin localization of PAX3-FOXO1, an oncogenic driver of childhood rhabdomyosarcoma (RMS), derived from a fusion of PFs. To quantitatively define its chromatin-targeting functions and capacity to drive epigenetic reprogramming, we developed a ChIP-seq workflow with per-cell normalization (pc-ChIP-seq). Our quantitative localization studies address structural variation in RMS genomes and reveal insights into inactive chromatin localization of PAX3-FOXO1. Taken together, our studies are consistent with pioneer function for a driver oncoprotein in RMS, with repressed chromatin binding and nucleosome-motif targeting. Elsevier 2021-07-16 /pmc/articles/PMC8346656/ /pubmed/34386729 http://dx.doi.org/10.1016/j.isci.2021.102867 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Sunkel, Benjamin D.
Wang, Meng
LaHaye, Stephanie
Kelly, Benjamin J.
Fitch, James R.
Barr, Frederic G.
White, Peter
Stanton, Benjamin Z.
Evidence of pioneer factor activity of an oncogenic fusion transcription factor
title Evidence of pioneer factor activity of an oncogenic fusion transcription factor
title_full Evidence of pioneer factor activity of an oncogenic fusion transcription factor
title_fullStr Evidence of pioneer factor activity of an oncogenic fusion transcription factor
title_full_unstemmed Evidence of pioneer factor activity of an oncogenic fusion transcription factor
title_short Evidence of pioneer factor activity of an oncogenic fusion transcription factor
title_sort evidence of pioneer factor activity of an oncogenic fusion transcription factor
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346656/
https://www.ncbi.nlm.nih.gov/pubmed/34386729
http://dx.doi.org/10.1016/j.isci.2021.102867
work_keys_str_mv AT sunkelbenjamind evidenceofpioneerfactoractivityofanoncogenicfusiontranscriptionfactor
AT wangmeng evidenceofpioneerfactoractivityofanoncogenicfusiontranscriptionfactor
AT lahayestephanie evidenceofpioneerfactoractivityofanoncogenicfusiontranscriptionfactor
AT kellybenjaminj evidenceofpioneerfactoractivityofanoncogenicfusiontranscriptionfactor
AT fitchjamesr evidenceofpioneerfactoractivityofanoncogenicfusiontranscriptionfactor
AT barrfredericg evidenceofpioneerfactoractivityofanoncogenicfusiontranscriptionfactor
AT whitepeter evidenceofpioneerfactoractivityofanoncogenicfusiontranscriptionfactor
AT stantonbenjaminz evidenceofpioneerfactoractivityofanoncogenicfusiontranscriptionfactor